EGFR is one of the biomarkers of the basal-like subtype of breast carcinomas and might play a relevant role in its biological behavior, being a potential therapeutic target to this aggressive ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

In recent years, CKD, which traditionally developed small-molecule ... targeting antibodies. CKD is currently developing CKD-702, a bispecific antibody directed against epidermal growth factor ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

an anti-EGFR IgA antibody that will now be developed under Epsilogen as EPS-401. The therapy is expected to enter the clinic ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...